166 related articles for article (PubMed ID: 18841471)
1. Plasma homovanillic acid and prolactin in Huntington's disease.
Markianos M; Panas M; Kalfakis N; Vassilopoulos D
Neurochem Res; 2009 May; 34(5):917-22. PubMed ID: 18841471
[TBL] [Abstract][Full Text] [Related]
2. Neuroendocrine evidence of normal hypothalamus-pituitary dopaminergic function in Huntington's disease.
Markianos M; Panas M; Kalfakis N; Hatzimanolis J; Vassilopoulos D
Neuro Endocrinol Lett; 2010; 31(3):359-62. PubMed ID: 20588235
[TBL] [Abstract][Full Text] [Related]
3. Plasma testosterone in male patients with Huntington's disease: relations to severity of illness and dementia.
Markianos M; Panas M; Kalfakis N; Vassilopoulos D
Ann Neurol; 2005 Apr; 57(4):520-5. PubMed ID: 15786456
[TBL] [Abstract][Full Text] [Related]
4. Clinical correlates of mitochondrial function in Huntington's disease muscle.
Turner C; Cooper JM; Schapira AH
Mov Disord; 2007 Sep; 22(12):1715-21. PubMed ID: 17557337
[TBL] [Abstract][Full Text] [Related]
5. Low plasma total cholesterol in patients with Huntington's disease and first-degree relatives.
Markianos M; Panas M; Kalfakis N; Vassilopoulos D
Mol Genet Metab; 2008 Mar; 93(3):341-6. PubMed ID: 18006350
[TBL] [Abstract][Full Text] [Related]
6. Autopsy-proven Huntington's disease with 29 trinucleotide repeats.
Kenney C; Powell S; Jankovic J
Mov Disord; 2007 Jan; 22(1):127-30. PubMed ID: 17115386
[TBL] [Abstract][Full Text] [Related]
7. Weight loss in Huntington disease increases with higher CAG repeat number.
Aziz NA; van der Burg JM; Landwehrmeyer GB; Brundin P; Stijnen T; ; Roos RA
Neurology; 2008 Nov; 71(19):1506-13. PubMed ID: 18981372
[TBL] [Abstract][Full Text] [Related]
8. Plasma prolactin and homovanillic acid as markers for psychopathology and abnormal movements after neuroleptic dose decrease.
Newcomer JW; Riney SJ; Vinogradov S; Csernansky JG
Psychopharmacol Bull; 1992; 28(1):101-7. PubMed ID: 1609034
[TBL] [Abstract][Full Text] [Related]
9. Female Sexual Dysfunction in Presymptomatic Mutation Carriers and Patients with Huntington's Disease.
Kolenc M; Kobal J; Podnar S
J Huntingtons Dis; 2017; 6(2):105-113. PubMed ID: 28482643
[TBL] [Abstract][Full Text] [Related]
10. Paradoxical delay in the onset of disease caused by super-long CAG repeat expansions in R6/2 mice.
Morton AJ; Glynn D; Leavens W; Zheng Z; Faull RL; Skepper JN; Wight JM
Neurobiol Dis; 2009 Mar; 33(3):331-41. PubMed ID: 19130884
[TBL] [Abstract][Full Text] [Related]
11. Growth hormone and ghrelin secretion are associated with clinical severity in Huntington's disease.
Aziz NA; Pijl H; Frölich M; Schröder-van der Elst JP; van der Bent C; Roelfsema F; Roos RA
Eur J Neurol; 2010 Feb; 17(2):280-8. PubMed ID: 19845749
[TBL] [Abstract][Full Text] [Related]
12. Dysfunctional Dopaminergic Neurones in Mouse Models of Huntington's Disease: A Role for SK3 Channels.
Dallérac GM; Levasseur G; Vatsavayai SC; Milnerwood AJ; Cummings DM; Kraev I; Huetz C; Evans KA; Walters SW; Rezaie P; Cho Y; Hirst MC; Murphy KP
Neurodegener Dis; 2015; 15(2):93-108. PubMed ID: 25871323
[TBL] [Abstract][Full Text] [Related]
13. The number of CAG repeats within the normal allele does not influence the age of onset in Huntington's disease.
Klempíř J; Zidovská J; Stochl J; Ing VK; Uhrová T; Roth J
Mov Disord; 2011 Jan; 26(1):125-9. PubMed ID: 21322024
[TBL] [Abstract][Full Text] [Related]
14. Clinical characterization of dystonia in adult patients with Huntington's disease.
van de Zande NA; Massey TH; McLauchlan D; Pryce Roberts A; Zutt R; Wardle M; Payne GC; Clenaghan C; Tijssen MAJ; Rosser AE; Peall KJ
Eur J Neurol; 2017 Sep; 24(9):1140-1147. PubMed ID: 28661018
[TBL] [Abstract][Full Text] [Related]
15. Aberrant connectivity of lateral prefrontal networks in presymptomatic Huntington's disease.
Wolf RC; Sambataro F; Vasic N; Schönfeldt-Lecuona C; Ecker D; Landwehrmeyer B
Exp Neurol; 2008 Sep; 213(1):137-44. PubMed ID: 18588876
[TBL] [Abstract][Full Text] [Related]
16. Parent-of-origin differences of mutant HTT CAG repeat instability in Huntington's disease.
Aziz NA; van Belzen MJ; Coops ID; Belfroid RD; Roos RA
Eur J Med Genet; 2011; 54(4):e413-8. PubMed ID: 21540131
[TBL] [Abstract][Full Text] [Related]
17. Plasma neurofilament heavy chain levels in Huntington's disease.
Wild EJ; Petzold A; Keir G; Tabrizi SJ
Neurosci Lett; 2007 May; 417(3):231-3. PubMed ID: 17363167
[TBL] [Abstract][Full Text] [Related]
18. Clinical and genetic characteristics in patients with Huntington's disease from China.
Yang J; Chen K; Wei Q; Chen Y; Cao B; Burgunder JM; Shang HF
Neurol Res; 2016 Oct; 38(10):916-20. PubMed ID: 27483361
[TBL] [Abstract][Full Text] [Related]
19. Plasma testosterone, dehydroepiandrosterone sulfate, and cortisol in female patients with Huntington's disease.
Markianos M; Panas M; Kalfakis N; Vassilopoulos D
Neuro Endocrinol Lett; 2007 Apr; 28(2):199-203. PubMed ID: 17435662
[TBL] [Abstract][Full Text] [Related]
20. Neurochemistry of dopamine in Huntington's dementia and normal aging.
Stahl SM; Thiemann S; Faull KF; Barchas JD; Berger PA
Arch Gen Psychiatry; 1986 Feb; 43(2):161-4. PubMed ID: 2936315
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
